News • Colon cancer

Biomarkers identify aggressive Tumors

The blood test can help with the difficult decision of whether early-stage patients should recieve chemotherapy.
pixabay

Early-stage colon cancer patients could benefit in the future from  specific genetic tests that forecast their prognosis and help them make  the right decision regarding chemotherapy.

Two of the biomarkers involved are the MACC1 gene, high levels of which promote aggressive tumor growth and the development of metastasis, and a defective DNA mismatch repair (dMMR) system, which plays a role in tumor formation. Life expectancy is longer for patients with dMMR tumors and with low MACC1 gene activity.

The blood test can indicate whether there is a higher risk of the tumor returning or metastasizing. It helps with the difficult decision of whether early-stage patients should receive chemotherapy.

Ulrike Stein

Blood tests can help predict chemotherapy success

In recent years, scientists have successfully identified genetic subtypes of malignant colon tumors, all of which carry a different prognosis for how the disease will develop. Up to 15 percent of these malignant tumors, for example, exhibit defective DNA repair mechanisms – known as DNA mismatch repair deficiency or dMMR. Another important biomarker is the gene MACC1 (metastasis-associated in colon cancer 1), which was identified by Ulrike Stein and her colleagues at MDC in 2009. There is now a patented blood test for MACC1 detection.

The five-year survival rate for patients with stage I-III colon cancer who exhibit low levels of MACC1 lies at 80 percent – in comparison to just 15 percent for patients with high MACC1 levels. “The blood test can indicate whether there is a higher risk of the tumor returning or metastasizing,” says Stein. “It helps with the difficult decision of whether early-stage patients should receive chemotherapy.” This now also includes patients in stage II of the disease with impaired DNA repair mechanisms.


Source: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft

28.07.2017

Related articles

Photo

News • Biomarker-based predictions

AI drives precision oncology for colorectal cancer

For the first time, researchers show that AI-based predictions can deliver comparable results to clinical tests on biopsies of patients with colorectal cancer (CRC).

Photo

News • New treatment approach

Colon cancer: Overcoming chemotherapy resistance

Colorectal cancer is one of the most common cancers. A team from the University of Geneva has found an alternative for patients who have developed resistance to chemotherapy treatments.

Photo

News • Chemotherapeutic delivery

Bowel cancer: Nanotechnology offers new hope

Bowel cancer survival rates could be improved if chemotherapy drugs were delivered via tiny nanoparticles to the diseased organs rather than oral treatment. That’s the finding from Indian and…

Related products

Subscribe to Newsletter